Status:
UNKNOWN
To Study the Role of Plasma Von Willebrand Factor Antigen (vWF) to A Disintegrin-like and Metalloproteinase With Thrombospondin Type-1 Motifs 13 (ADAMTS-13) Activity Ratio as a Predictor of Development of Extrahepatic Organ Failure in Acute on Chronic Liver Failure (ACLF) Patients.
Lead Sponsor:
Institute of Liver and Biliary Sciences, India
Conditions:
Acute on Chronic Liver Failure
Eligibility:
All Genders
18+ years
Brief Summary
Acute on chronic liver failure (ACLF) is a syndrome characterized by acute decompensation of chronic liver disease associated with organ failures and high short- term mortality. Development of systemi...
Detailed Description
Null Hypothesis: Systemic inflammation in acute-on-chronic liver failure (ACLF) leads to endothelial injury leading to increased vWF levels and exhaustion of its cleaving protein ADAMTS 13 which prom...
Eligibility Criteria
Inclusion
- \- All the patients with age \>18 years who are diagnosed having ACLF fulfilling APASL ACLF criteria and do not have any extrahepatic organ failure at enrollment.
Exclusion
- Patients on antiplatelet or anticoagulant therapy for at any point of time in last 7 days
- Pregnant female
- Patient receiving N-acetyl cysteine (NAC) (interferes with the vWF assay)
Key Trial Info
Start Date :
October 7 2023
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
50 Patients enrolled
Trial Details
Trial ID
NCT06066814
Start Date
October 7 2023
End Date
December 31 2023
Last Update
October 4 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Institute of Liver & Biliary Sciences.
New Delhi, National Capital Territory of Delhi, India, 110070